---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-012201"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:16:33.629446+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024

## Summary
- Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.
- Total revenues fell 59% YoY to approx $0.8M; R&D expenses rose 32% on severance and PRGN-2012 trial costs.
- Strategic reprioritization focuses on PRGN-2012 BLA submission under accelerated path H2 2024; workforce reduced >20%.
- Appointed Phil Tennant as CCO for potential PRGN-2012 commercial launch; raised $31.4M net in August public offering.
- Cash runway expected into early 2025; ActoBio subsidiary shut down, IP portfolio available for sale.

## SEC filing metadata
- accession: 0000950103-24-012201
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324012201/0000950103-24-012201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324012201/dp216654_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-012201
- JSON: https://secwatch.observer/filing/0000950103-24-012201.json
- Plain text: https://secwatch.observer/filing/0000950103-24-012201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.